Rydapt is a multiple kinase inhibitor that interferes with cellular signal transduction pathways. While the drug exhibits efficacy against a number of kinases, its efficacy against FLT3 is of particular relevance to AML (Fathi and Chen, 2011). Patients with FLT3-mutated AML represent a key population subtype, and mutations in FLT3, specifically the FLT3- internal tandem duplication (ITD) mutation, can lead to poorer disease prognosis than in patients with wild-type FLT3.
Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is Suite 1, 3rd Floor, 11 - 12 St. James's Square, London, England, SW1Y 4LB. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.